Zoetis (NYSE:ZTS) had its price target boosted by analysts at BMO Capital Markets to $78.00 in a research note issued on Tuesday, The Fly reports. The brokerage currently has a “market perform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 5.06% from the stock’s current price.
Other research analysts also recently issued reports about the company. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a research note on Tuesday, September 26th. BidaskClub downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research note on Thursday, October 12th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Tuesday, October 24th. Finally, Jefferies Group reissued a “buy” rating on shares of Zoetis in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $71.28.
Zoetis (ZTS) traded up $0.88 during midday trading on Tuesday, hitting $74.24. The company’s stock had a trading volume of 3,631,500 shares, compared to its average volume of 2,559,100. Zoetis has a 1 year low of $52.00 and a 1 year high of $74.42. The company has a market cap of $36,500.00, a price-to-earnings ratio of 39.07, a PEG ratio of 1.91 and a beta of 1.06. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.
Several institutional investors have recently modified their holdings of ZTS. Northwestern Mutual Wealth Management Co. raised its stake in shares of Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Zoetis in the third quarter worth approximately $114,000. Harfst & Associates Inc. raised its stake in shares of Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. raised its stake in shares of Zoetis by 86.5% in the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after purchasing an additional 1,040 shares during the last quarter. 93.19% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This article was originally reported by American Market News and is the sole property of of American Market News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/09/zoetis-zts-price-target-increased-to-78-00-by-analysts-at-bmo-capital-markets.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
